universe pharmaceuticals inc - UPC

UPC

Close Chg Chg %
3.74 0.55 14.71%

Closed Market

4.29

+0.55 (14.71%)

Volume: 110.25K

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Company Overview: universe pharmaceuticals inc - UPC

UPC Key Data

Open

$3.78

Day Range

3.78 - 4.50

52 Week Range

2.51 - 28.00

Market Cap

$2.10M

Shares Outstanding

563.34K

Public Float

552.61K

Beta

1.52

Rev. Per Employee

N/A

P/E Ratio

0.00

EPS

N/A

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

58.96K

 

UPC Performance

1 Week
 
14.93%
 
1 Month
 
8.76%
 
3 Months
 
-3.49%
 
1 Year
 
-82.78%
 
5 Years
 
N/A
 

UPC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About universe pharmaceuticals inc - UPC

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

UPC At a Glance

Universe Pharmaceuticals, Inc.
265 Jingjiu Avenue
Ji'an, Jiangxi 343100
Phone 86-796-8403309 Revenue 23.02M
Industry Pharmaceuticals: Major Net Income -8,727,298.00
Sector Health Technology Employees 225
Fiscal Year-end 09 / 2025
View SEC Filings

UPC Valuation

P/E Current 0.00
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.00
Price to Book Ratio 0.00
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 2.854
Enterprise Value to Sales -0.934
Total Debt to Enterprise Value -0.372

UPC Efficiency

Revenue/Employee 102,330.924
Income Per Employee -38,787.991
Receivables Turnover 1.24
Total Asset Turnover 0.38

UPC Liquidity

Current Ratio 2.542
Quick Ratio 2.408
Cash Ratio 1.452

UPC Profitability

Gross Margin 25.294
Operating Margin -34.832
Pretax Margin -35.408
Net Margin -37.904
Return on Assets -14.397
Return on Equity -20.526
Return on Total Capital -16.314
Return on Invested Capital -20.023

UPC Capital Structure

Total Debt to Total Equity 17.569
Total Debt to Total Capital 14.943
Total Debt to Total Assets 11.764
Long-Term Debt to Equity 4.697
Long-Term Debt to Total Capital 3.996
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Universe Pharmaceuticals Inc - UPC

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
47.98M 40.14M 32.31M 23.02M
Sales Growth
+56.27% -16.34% -19.52% -28.74%
Cost of Goods Sold (COGS) incl D&A
22.85M 18.46M 22.23M 17.20M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
446.88K 533.95K 508.79K 485.73K
Depreciation
441.36K 528.92K 503.69K 474.03K
Amortization of Intangibles
5.52K 5.03K 5.10K 11.70K
COGS Growth
+35.87% -19.21% +20.44% -22.63%
Gross Income
25.14M 21.69M 10.08M 5.82M
Gross Income Growth
+80.97% -13.73% -53.53% -42.21%
Gross Profit Margin
+52.38% +54.02% +31.19% +25.29%
2021 2022 2023 2024 5-year trend
SG&A Expense
11.32M 28.92M 13.43M 13.60M
Research & Development
5.45M 7.62M 4.82M 2.99M
Other SG&A
5.87M 21.30M 8.61M 10.60M
SGA Growth
+225.11% +155.44% -53.57% +1.28%
Other Operating Expense
223.98K 205.58K 179.19K 246.24K
Unusual Expense
- - - -
-
EBIT after Unusual Expense
13.59M (7.44M) (3.53M) (8.02M)
Non Operating Income/Expense
159.12K (421.54K) (197.08K) 145.48K
Non-Operating Interest Income
- - - 239.55K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
101.60K 162.40K 156.79K 278.17K
Interest Expense Growth
-17.90% +59.84% -3.46% +77.42%
Gross Interest Expense
101.60K 162.40K 156.79K 278.17K
Interest Capitalized
- - - -
-
Pretax Income
13.65M (8.02M) (3.88M) (8.15M)
Pretax Income Growth
+35.41% -158.78% +51.63% -110.08%
Pretax Margin
+28.44% -19.99% -12.01% -35.41%
Income Tax
2.36M 752.42K 2.31M 606.70K
Income Tax - Current - Domestic
- 3.03M 1.36M 685.94K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(668.34K) (605.28K) 1.63M 606.70K
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
11.32M (8.74M) (6.16M) (8.73M)
Minority Interest Expense
- - - -
-
Net Income
11.32M (8.74M) (6.16M) (8.73M)
Net Income Growth
+49.77% -177.18% +29.46% -41.61%
Net Margin Growth
+23.59% -21.76% -19.08% -37.90%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
11.32M (8.74M) (6.16M) (8.73M)
Preferred Dividends
- - - -
-
Net Income Available to Common
11.32M (8.74M) (6.16M) (8.73M)
EPS (Basic)
1873.6559 -1446.0479 -1020.0899 -376176.6172
EPS (Basic) Growth
+51.84% -177.18% +29.46% -36,776.81%
Basic Shares Outstanding
6.04K 6.04K 6.04K 23.200001160000003
EPS (Diluted)
1873.6559 -1446.0479 -1020.0899 -376176.6172
EPS (Diluted) Growth
+51.84% -177.18% +29.46% -36,776.81%
Diluted Shares Outstanding
6.04K 6.04K 6.04K 23.200001160000003
EBITDA
14.04M (6.90M) (3.02M) (7.53M)
EBITDA Growth
+31.66% -149.19% +56.29% -149.64%
EBITDA Margin
+29.25% -17.20% -9.34% -32.72%

Universe Pharmaceuticals Inc in the News